abstract |
The present application relates to ultra-pure compositions containing N 4 -(cyclopropylmethyl)-6-[(3R)-3-(memylamino)pyrrolidin-1-yl]pyrimidine-2,4-diamine tartrate dihydrate, methods of making the same, formulations containing the same, methods of using the same to treat H 4 -mediated diseases and conditions, and alternative salt forms thereof. |